Rekvina Labs Ltd Valuation
VINRKLB · Healthcare · Current price ₹53.83
Is Rekvina Labs Ltd undervalued?
DocStoX estimates the fair value of Rekvina Labs Ltd at ₹12 per share, versus the current market price of ₹54. That puts the stock about -77.7% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹12). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹10 (bear) to ₹12 (base) to ₹14 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
Rekvina Labs Ltd trades at a P/E of — and a P/B of 13.8x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on Rekvina Labs Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.